Literature DB >> 34009511

Comparison of Visual Outcome After Hyperopic LASIK Using a Wavefront-Optimized Platform Versus Other Excimer Lasers in the Past Two Decades.

Majid Moshirfar1,2,3, Alin Megerdichian4, William B West5, Chase M Miller6, Ronald Alek Sperry7, Calvin D Neilsen7, Mitchell T Tingey8, Phillip C Hoopes9.   

Abstract

INTRODUCTION: Laser-assisted in-situ keratomileusis (LASIK) for the correction of hyperopia and hyperopic astigmatism is challenging and has been less studied than for the correction of myopia and myopic astigmatism. The aim of this study was to analyze the refractive outcomes of LASIK in hyperopia and hyperopic astigmatic eyes using a wave-front optimized laser platform (the Allegretto EX500 laser) and perform a historical comparison with other excimer lasers within the past two decades.
METHODS: A one-center (Tertiary Refractive Center, Draper, Utah), retrospective, non-comparative study was conducted on 379 eyes treated with LASIK for hyperopia and hyperopic astigmatism. The data retrieved on these eyes were analyzed using uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and spherical equivalents. A literature search of excimer platforms in use in the past 20 years and a comparison of US Federal Drug Administration-approved platforms for hyperopia were performed.
RESULTS: At 3 and 12 months postoperatively, 142 (66%) and 81 (69%) eyes had a UDVA of 20/20 or better and 207 (96%) and 114 (97%) eyes had a UDVA of 20/40 or better, respectively. The mean refractive spherical equivalent was - 0.52 ± 0.78 D at 3 months and - 0.46 ± 0.79 D at 12 months. At 12 months, 181 (96%) eyes achieved a spherical equivalent within ± 1.00 D of the intended target. Studies published before 2005 reported lower rates of UDVA 20/20 or better (32%) compared to those published after (68%); however, this discrepancy was less evident for UDVA 20/40 or better. A similar trend towards improved accuracy was noted in the literature with postoperative manifest refractive spherical equivalent within ± 0.50 D before and after 2005.
CONCLUSION: There has been significant improvement in safety, efficacy, stability, and accuracy of LASIK treatment for hyperopia and hyperopic astigmatism within the past two decades. Newer excimer lasers meet industry standards and in particular, the Allegretto EX500 used in this study exceeded industry standards.

Entities:  

Keywords:  Allegretto EX500 laser; Hyperopic astigmatism; LASIK; Wave-front optimized laser platform

Year:  2021        PMID: 34009511     DOI: 10.1007/s40123-021-00346-1

Source DB:  PubMed          Journal:  Ophthalmol Ther


  3 in total

1.  Four-year postoperative results of the US ALLEGRETTO WAVE clinical trial for the treatment of hyperopia.

Authors:  Guy M Kezirian; Charles R Moore; Karl G Stonecipher
Journal:  J Refract Surg       Date:  2008-04       Impact factor: 3.573

2.  Two-year follow-up of laser in situ keratomileusis for hyperopia.

Authors:  S Esquenazi; A Mendoza
Journal:  J Refract Surg       Date:  1999 Nov-Dec       Impact factor: 3.573

3.  Laser in situ keratomileusis for hyeropia and hyperopic astigmatism.

Authors:  M C Arbelaez; M C Knorz
Journal:  J Refract Surg       Date:  1999 Jul-Aug       Impact factor: 3.573

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.